Chemerin regulates normal angiogenesis and hypoxia-driven neovascularization.

Authors:
Ben Dhaou C; Mandi K; Frye M; Acheampong A; Radi A and 5 more

Journal:
Angiogenesis

Publication Year: 2021

DOI:
10.1007/s10456-021-09818-1

PMCID:
PMC9054887

PMID:
34524600

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Angiogenesis

Abbreviation: Angiogenesis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Aging impairs the ability of vascular endothelial stem cells to generate endothelial cells in mice.
Shimizu S; Iba T; Naito H and 5 more (2023) - Transparency Score: 4/6
Damage to endothelial barriers and its contribution to long COVID.
Wu X; Xiang M; Jing H and 3 more (2023) - Transparency Score: 2/6
Executive summary of the 14th HHT international scientific conference.
Ola R; Hessels J; Hammill A and 6 more (2023) - Transparency Score: 3/6
Localized conditional induction of brain arteriovenous malformations in a mouse model of hereditary…
Scherschinski L; Han C; Kim YH and 6 more (2023) - Transparency Score: 3/6
Loss of GLTSCR1 causes congenital heart defects by regulating NPPA transcription.
Han F; Yang B; Chen Y and 10 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestM.P. is C.E.O. of the biotech company Gepeceron. All other authors declare no conflict of interests. Ethical ApprovalAll animal experiments were conducted in accordance with European guidelines and local regulations and approved by the local ethics committee (Commission d’Ethique du Bien-Etre Animal, CEBEA) of the ULB Medical School (N° 660 and 707 N). All efforts were made to minimize suffering. Conflict of interest M.P. is C.E.O. of the biotech company Gepeceron. All other authors declare no conflict of interests."

Evidence found in paper:

"Funding This work was supported by the Fonds National de la Recherche Scientifique of Belgium (Grant Welbio 2017-CR-2019 C-03R) to M.P. C.B.D. was supported by a FNRS-Télévie Grant (7.6520.19 F)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025